The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...
The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...
Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...